Healthcare provider profile · identity verified

Prakash Samuel Eapen, M.D.

Internal Medicine · AUSTIN, TX · NPI 1255595435

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	557	168
Amlodipine Besylate	Amlodipine Besylate	352	107
Rosuvastatin Calcium	Rosuvastatin Calcium	334	97
Ozempic	Semaglutide	274	48
Fluticasone Propionate	Fluticasone Propionate	259	104
Lisinopril	Lisinopril	233	71
Losartan Potassium	Losartan Potassium	226	67
Levothyroxine Sodium	Levothyroxine Sodium	221	71
Albuterol Sulfate Hfa	Albuterol Sulfate	204	68
Jardiance	Empagliflozin	202	62
Metformin Hcl	Metformin Hcl	196	57
Montelukast Sodium	Montelukast Sodium	195	61
Gabapentin	Gabapentin	177	59
Carvedilol	Carvedilol	169	51
Famotidine	Famotidine	162	54
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	154	35
Tamsulosin Hcl	Tamsulosin Hcl	149	45
Metoprolol Succinate	Metoprolol Succinate	145	38
Pantoprazole Sodium	Pantoprazole Sodium	141	49
Tramadol Hcl	Tramadol Hcl	127	35
Pravastatin Sodium	Pravastatin Sodium	126	39
Trazodone Hcl	Trazodone Hcl	112	39
Naproxen	Naproxen	100	35
Ezetimibe	Ezetimibe	98	32
Glipizide Er	Glipizide	94	28
Mounjaro	Tirzepatide	93	17
Trulicity	Dulaglutide	93	15
Omeprazole	Omeprazole	90	42
Alendronate Sodium	Alendronate Sodium	84	21
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	79	24
Pregabalin	Pregabalin	79	19
Metformin Hcl Er	Metformin Hcl	78	23
Duloxetine Hcl	Duloxetine Hcl	74	26
Clotrimazole	Clotrimazole	69	31
Hydroxyzine Hcl	Hydroxyzine Hcl	69	25
Hydralazine Hcl	Hydralazine Hcl	68	21
Spironolactone	Spironolactone	65	17
Topiramate	Topiramate	65	21
Tresiba Flextouch U-100	Insulin Degludec	62	15
Furosemide	Furosemide	61	27
Sertraline Hcl	Sertraline Hcl	61	21
Tizanidine Hcl	Tizanidine Hcl	60	17
Vitamin D2	Ergocalciferol (Vitamin D2)	60	36
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	59	28
Escitalopram Oxalate	Escitalopram Oxalate	59	21
Methocarbamol	Methocarbamol	58	26
Diclofenac Sodium	Diclofenac Sodium	56	26
Triamcinolone Acetonide	Triamcinolone Acetonide	56	35
Finasteride	Finasteride	54	16
Meloxicam	Meloxicam	54	18
Vascepa	Icosapent Ethyl	54	14
Baclofen	Baclofen	50	15
Nifedipine Er	Nifedipine	50	20
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	49	24
Synthroid	Levothyroxine Sodium	48	14
Clopidogrel	Clopidogrel Bisulfate	46	15
Hydrochlorothiazide	Hydrochlorothiazide	46	18
Chlorthalidone	Chlorthalidone	44	17
Humalog Kwikpen U-100	Insulin Lispro	44	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	44	32
Azelastine Hcl	Azelastine Hcl	43	14
Celecoxib	Celecoxib	43	suppressed
Januvia	Sitagliptin Phosphate	42	13
Olmesartan Medoxomil	Olmesartan Medoxomil	42	15
Ondansetron Odt	Ondansetron	42	12
Memantine Hcl	Memantine Hcl	41	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	41	suppressed
Valsartan	Valsartan	40	12
Acyclovir	Acyclovir	38	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	38	13
Bupropion Xl	Bupropion Hcl	38	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	38	12
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	36	suppressed
Mirtazapine	Mirtazapine	36	17
Telmisartan	Telmisartan	36	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	34	11
Alfuzosin Hcl Er	Alfuzosin Hcl	33	11
Allopurinol	Allopurinol	33	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	22
Buspirone Hcl	Buspirone Hcl	33	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	33	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	33	11
Rybelsus	Semaglutide	33	suppressed
Ibuprofen	Ibuprofen	32	13
Janumet	Sitagliptin Phos/Metformin Hcl	32	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	13
Prednisone	Prednisone	32	24
Terbinafine Hcl	Terbinafine Hcl	32	31
Xarelto	Rivaroxaban	32	suppressed
Meclizine Hcl	Meclizine Hcl	31	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	31	suppressed
Potassium Chloride	Potassium Chloride	30	18
Combivent Respimat	Ipratropium/Albuterol Sulfate	28	suppressed
Azithromycin	Azithromycin	27	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	25	suppressed
Synjardy	Empagliflozin/Metformin Hcl	25	suppressed
Mupirocin	Mupirocin	24	14
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Varenicline Tartrate	Varenicline Tartrate	23	suppressed
Verapamil Er	Verapamil Hcl	23	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	22	16
Atenolol	Atenolol	22	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	22	suppressed
Felodipine Er	Felodipine	22	suppressed
Lactulose	Lactulose	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Ammonium Lactate	Ammonium Lactate	20	suppressed
Cephalexin	Cephalexin	20	17
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Estradiol	Estradiol	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Incontrol Pen Needle	Pen Needle, Diabetic	19	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	19	suppressed
Spiriva Handihaler	Tiotropium Bromide	19	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	19	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Lamotrigine	Lamotrigine	18	suppressed
Levemir Flexpen	Insulin Detemir	18	13
Novolog Flexpen	Insulin Aspart	18	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Eliquis	Apixaban	17	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Xifaxan	Rifaximin	16	suppressed
Insulin Aspart Flexpen	Insulin Aspart	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Primidone	Primidone	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Glipizide	Glipizide	14	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	14	suppressed
Ciclopirox	Ciclopirox Olamine	13	suppressed
Dulera	Mometasone/Formoterol	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Torsemide	Torsemide	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Kerendia	Finerenone	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Clonidine	Clonidine	11	suppressed
Lyrica	Pregabalin	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error